Dillon Alexander B, Douglass Alexzandra, Jabbour Pascal, Shields Carol L
School of Medicine, New York University, New York, USA.
Ocular Oncology Service, Wills Eye Institute, Thomas Jefferson University, Philadelphia, USA.
Oman J Ophthalmol. 2016 Sep-Dec;9(3):164-166. doi: 10.4103/0974-620X.192278.
Two infants with retinoblastoma and 13q syndrome with multiorgan system anomalies were treated with targeted intra-arterial chemotherapy (IAC) using one-to-three cycles of melphalan 5 mg to avoid systemic chemotherapeutic side effects. Both patients showed good response, with tumor control and no systemic chemotherapy side effects. Of the treatment modalities currently available, IAC may represent an optimal balance between tumor extermination and adverse drug reactions in this patient population with classically reduced multiorgan reserve.
两名患有视网膜母细胞瘤和伴有多器官系统异常的13q综合征的婴儿接受了靶向动脉内化疗（IAC），使用一至三个周期的美法仑5毫克，以避免全身化疗的副作用。两名患者均显示出良好的反应，肿瘤得到控制且无全身化疗副作用。在目前可用的治疗方式中，IAC可能代表了在这类典型的多器官储备降低的患者群体中，肿瘤根除与药物不良反应之间的最佳平衡。
